The Biden Administration, after setting its sights on America’s pharmaceutical supply chains last winter, is telegraphing its next move to restore the United States’ drugmaking prowess.
President Joe Biden penned an executive order Monday to boost biotechnology and biomanufacturing across a range of areas in the U.S.
To help the U.S. biotech sector reach its full potential, the U.S. needs to funnel cash toward development of genetic engineering tech, use approaches like artificial intelligence to “unlock the power of biological data,” and “scale-up production,” whilst simultaneously breaking down obstacles to commercialization so that innovative products can hit the market faster, Biden said in a White House release.
Read the full article at: www.fiercepharma.com
